2.50
Hdl Handle:
http://hdl.handle.net/10755/601987
Category:
Full-text
Format:
Text-based Document
Type:
Presentation
Title:
Symptoms in Breast Cancer Survivors Who Have Completed Primary Therapy
Other Titles:
Screening and Surviving Breast Cancer: Promoting Health through Vigilance [Session]
Author(s):
Strunk, Faith A.; Wood, Geri; Armstrong, Terri S.; Theriault, Richard L.; Urbauer, Diana L.; Fellman, Bryan M.
Lead Author STTI Affiliation:
Zeta Pi
Author Details:
Faith A. Strunk, RN, AOCNP, faith.a.strunk@uth.tmc.edu; Geri Wood, RN, FAAN; Terri S. Armstrong, RN, ANP-BC, FAANP, FAAN; Richard L. Theriault; Diana L. Urbauer; Bryan M. Fellman
Abstract:
Session presented on Friday, July 24, 2015: Purpose: The purpose of this study was to determine whether symptom burden differed according to survivor status (early [less than 3 years post completion of primary therapy], as opposed to long-term [years 3 through 5], survival) and/or use of endocrine or hormonal adjuvant therapy. ??Methods: In this exploratory, cross-sectional study, data were collected on 133 survivors, using the MD Anderson Symptom Inventory, Karnofsky Performance Status, Charlson Comorbidity Index and a demographic/health history form. We analyzed symptom burden by survivor status and use of adjuvant therapy utilizing a 2-way ANOVA model. ??Results: Patients who were prescribed endocrine or hormonal therapy had higher symptom severity and burden scores than did women who did not receive these therapies. No differences were noted in symptom burden, symptom severity and composite interference score between early- and long-term survivors. As functional status increased, the patients??? symptoms scores decreased. Comorbidities did not impact symptoms.?????? ??Conclusions: Breast cancer survivors continue to experience symptoms, up to 6 years after completing primary therapy, but symptoms are more severe among those taking hormonal or endocrine therapy. Understanding the relationship between symptoms, cancer therapy, comorbidities, and functional status in early versus late survivorship may improve symptom management and outcomes for breast cancer survivors.
Keywords:
breast cancer; survivorship; symptom burden
Repository Posting Date:
17-Mar-2016
Date of Publication:
17-Mar-2016 ; 17-Mar-2016
Other Identifiers:
INRC15D16
Conference Date:
2015
Conference Name:
26th International Nursing Research Congress
Conference Host:
Sigma Theta Tau International, the Honor Society of Nursing
Conference Location:
San Juan, Puerto Rico
Description:
Research Congress 2015 Theme: Question Locally, Engage Regionally, Apply Globally. Held at the Puerto Rico Convention Center.

Full metadata record

DC FieldValue Language
dc.language.isoenen
dc.type.categoryFull-texten
dc.formatText-based Documenten
dc.typePresentationen
dc.titleSymptoms in Breast Cancer Survivors Who Have Completed Primary Therapyen
dc.title.alternativeScreening and Surviving Breast Cancer: Promoting Health through Vigilance [Session]en
dc.contributor.authorStrunk, Faith A.en
dc.contributor.authorWood, Gerien
dc.contributor.authorArmstrong, Terri S.en
dc.contributor.authorTheriault, Richard L.en
dc.contributor.authorUrbauer, Diana L.en
dc.contributor.authorFellman, Bryan M.en
dc.contributor.departmentZeta Pien
dc.author.detailsFaith A. Strunk, RN, AOCNP, faith.a.strunk@uth.tmc.edu; Geri Wood, RN, FAAN; Terri S. Armstrong, RN, ANP-BC, FAANP, FAAN; Richard L. Theriault; Diana L. Urbauer; Bryan M. Fellmanen
dc.identifier.urihttp://hdl.handle.net/10755/601987-
dc.description.abstractSession presented on Friday, July 24, 2015: Purpose: The purpose of this study was to determine whether symptom burden differed according to survivor status (early [less than 3 years post completion of primary therapy], as opposed to long-term [years 3 through 5], survival) and/or use of endocrine or hormonal adjuvant therapy. ??Methods: In this exploratory, cross-sectional study, data were collected on 133 survivors, using the MD Anderson Symptom Inventory, Karnofsky Performance Status, Charlson Comorbidity Index and a demographic/health history form. We analyzed symptom burden by survivor status and use of adjuvant therapy utilizing a 2-way ANOVA model. ??Results: Patients who were prescribed endocrine or hormonal therapy had higher symptom severity and burden scores than did women who did not receive these therapies. No differences were noted in symptom burden, symptom severity and composite interference score between early- and long-term survivors. As functional status increased, the patients??? symptoms scores decreased. Comorbidities did not impact symptoms.?????? ??Conclusions: Breast cancer survivors continue to experience symptoms, up to 6 years after completing primary therapy, but symptoms are more severe among those taking hormonal or endocrine therapy. Understanding the relationship between symptoms, cancer therapy, comorbidities, and functional status in early versus late survivorship may improve symptom management and outcomes for breast cancer survivors.en
dc.subjectbreast canceren
dc.subjectsurvivorshipen
dc.subjectsymptom burdenen
dc.date.available2016-03-17T13:00:51Zen
dc.date.issued2016-03-17-
dc.date.issued2016-03-17en
dc.date.accessioned2016-03-17T13:00:51Zen
dc.conference.date2015en
dc.conference.name26th International Nursing Research Congressen
dc.conference.hostSigma Theta Tau International, the Honor Society of Nursingen
dc.conference.locationSan Juan, Puerto Ricoen
dc.descriptionResearch Congress 2015 Theme: Question Locally, Engage Regionally, Apply Globally. Held at the Puerto Rico Convention Center.en
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.